Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Novartis
Moodys
Cantor Fitzgerald
Daiichi Sankyo
Chubb
QuintilesIMS
Farmers Insurance
Colorcon
Citi

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,585,493 protect, and when does it expire?


Patent ► Subscribe protects ADASUVE and is included in one NDA.

This patent has one hundred and ninety-four patent family members in nineteen countries.

Summary for Patent: ► Subscribe

Title:Thin-film drug delivery article and method of use
Abstract: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 .mu.m. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.
Inventor(s): Hale; Ron L. (Woodside, CA), Lu; Amy (Los Altos, CA), Myers; Daniel J. (Mountain View, CA), Rabinowitz; Joshua D. (Mountain View, CA), Wensley; Martin J. (San Francisco, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:10/633,877
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,070,761Delivery of nonsteroidal antiinflammatory drugs through an inhalation route► Subscribe
7,005,122Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route► Subscribe
6,737,043 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route► Subscribe
8,955,512Method of forming an aerosol for inhalation delivery► Subscribe
7,014,841Delivery of antiemetics through an inhalation route► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia2052753► Subscribe
Portugal2052753► Subscribe
Portugal1389098► Subscribe
Portugal1389096► Subscribe
Poland374048► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Citi
Merck
QuintilesIMS
US Department of Justice
Deloitte
Argus Health
Baxter
McKinsey
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot